# CLL13 (NCT02950051)

> Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

No report yet. It can be ordered.

- Drugs tested: venetoclax plus obinutuzumab plus ibrutinib; venetoclax plus obinutuzumab; venetoclax plus rituximab
- Indication: previously untreated CLL without del(17p) or TP53 mutation

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02950051
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: German CLL Study Group
- Conditions: Chronic Lymphocytic Leukemia
- Interventions: Fludarabine; Cyclophosphamide; Rituximab; Bendamustine; Venetoclax; Obinutuzumab; Ibrutinib
- Enrollment: 926
- Primary outcome: Miminimal residual disease (MRD) negativity rate in peripheral blood (PB)
- Primary outcome: Progression free survival (PFS)

## Questions raised in the commentary

_Automated from the 40 newest of 167 indexed sources (Dec 2025 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether MRD should guide treatment decisions after fixed-duration therapy
- Whether adding BTK inhibition justifies the added treatment burden
- Whether fixed-duration therapy offers a better tradeoff than continuous treatment

Also discussed: post-progression treatment sequencing.

## Indexed commentary on CLL13 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 77
- Podcasts: 49
- X threads: 30
- Bluesky threads: 11

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=cll13-nct02950051

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02950051", "email": "<work email>"}; the inbox owner confirms by the emailed link.